Immune checkpoint blockade therapies, using antibodies against PD-1 and CTLA-4, have been shown to facilitate the continuous recruitment of T cells into tumors, contributing to significant anti-tumor effects [61]. The gene discussed is CTLA4; the disease is neoplasm.